Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.40 USD
+0.47 (1.57%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $30.38 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Immunovant, Inc. (IMVT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$48.87 | $60.00 | $36.00 | 63.28% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Immunovant, Inc. comes to $48.87. The forecasts range from a low of $36.00 to a high of $60.00. The average price target represents an increase of 63.28% from the last closing price of $29.93.
Analyst Price Targets (15)
Broker Rating
Immunovant, Inc. currently has an average brokerage recommendation (ABR) of 1.06 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 15 recommendations.
Of the 16 recommendations deriving the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 93.75% and 6.25% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 15 |
Buy | 1 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.06 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/10/2024 | Raymond James | Danielle Brill | Not Available | Moderate Buy |
10/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/11/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
9/11/2024 | UBS | Ashwani Verma | Not Available | Strong Buy |
9/10/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
9/9/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
9/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
9/9/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
7/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/30/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
5/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/13/2024 | Goldman Sachs | Christopher Johnson | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.06 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 16 |
Average Target Price | $48.87 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.61 |
IMVT FAQs
Immunovant, Inc. (IMVT) currently has an average brokerage recommendation (ABR) of 1.06 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms.
The average price target for Immunovant, Inc. (IMVT) is $48.87. The current on short-term price targets is based on 11 reports.
The forecasts for Immunovant, Inc. (IMVT) range from a low of $36 to a high of $60. The average price target represents a increase of $60.76 from the last closing price of $30.40.
The current UPSIDE for Immunovant, Inc. (IMVT) is 60.76%
Based on short-term price targets offered by 15 analysts, the average price target for Immunovant, Inc. comes to $48.87. The forecasts range from a low of $36.00 to a high of $60.00. The average price target represents an increase of 63.28% from the last closing price of $29.93.